Cardiology in Maryland

Ambu A/S is the global market leader in single-use endoscopy, a category the company created in 2009. The company manufactures and distributes a comprehensive portfolio of single-use (disposable) endoscopic devices and airway management solutions for hospitals, emergency care settings, and training environments. Core product lines include the aScope™ family of flexible endoscopes for pulmonology (bronchoscopy), gastroenterology (gastroscopy), urology (cystoscopy), and ENT applications, as well as rigid and semi-rigid visualization systems. Specialty products include the aScope™ 5 Broncho with color-coded sizing, aScope™ Gastro Large for therapeutic gastroscopy, aScope™ 5 Cysto HD for urology with superior image quality, and the aScope™ 4 Broncho Sampler Set for improved BAL/BW workflow. The company also offers airway management solutions, including the SureSight™ Connect video laryngoscope for intubation and upper airway visualization. Ambu serves multiple clinical specialties: pulmonology, ENT, gastroenterology, urology, neurology, cardiology, and anesthesia. The company has received recognition for technology innovation, earning the 2025 Frost & Sullivan Technology Innovation Leadership Recognition in the European single-use endoscopy industry. All products are single-use, sterile, and designed to eliminate cross-contamination risks associated with reusable instruments. Ambu operates globally with local representatives and maintains both hospital and emergency/training market segments.

Guangzhou Wondfo Biotech Co., Ltd. is a leading in vitro diagnostics (IVD) manufacturer headquartered in Guangzhou, China, founded in 1992. The company employs over 3,000 staff and operates 20+ subsidiaries across 150+ countries. Wondfo specializes in point-of-care testing (POCT) and clinical laboratory diagnostics across eight major technology platforms: Colloidal Gold (rapid diagnostic tests for infectious disease, fertility, drugs-of-abuse); Immunofluorescence (50+ assay reagents and 7 high-performance analyzers for cardiovascular, inflammatory, renal, endocrine, and oncology biomarkers); Chemiluminescence (single-dose immunoassay analyzers with maintenance-free design); Coagulation (optical and semi-automatic blood coagulation analyzers for PT, APTT, TT, FIB, ACT); Blood Gas (portable BGA-102 analyzer delivering results in 30 seconds); Molecular Diagnostics (RT-PCR reagents and platforms for infectious disease including COVID-19); Pathology (PA-3600 automated immunohistochemical staining system); and HPLC Hemoglobin (Truth-H80E analyzer for HbA1c measurement within 60-90 seconds for diabetes diagnosis and monitoring). Products are distributed through clinical laboratories, hospitals, point-of-care settings, emergency departments, and ICUs globally. The Finecare Meter series holds the largest installed base in Chinese medical institutions. Wondfo holds WHO prequalification for select infectious disease products and maintains CE and regulatory compliance across major markets. The company supports healthcare systems with integrated POCT lab solutions and participates actively in international clinical laboratory and diagnostics conferences.

Radiopharmaceutical Imaging and Dosimetry (Rapid), LLC is a Baltimore-based biotechnology research company founded by Johns Hopkins University experts (Drs. George Sgouros, Eric Frey, and Michael Ghaly). Rapid specializes in quantitative imaging, dosimetry analysis, and precision medicine support for radiopharmaceutical therapies, particularly in oncology. The company provides comprehensive consulting and centralized solutions covering the full workflow from image acquisition protocol development through regulatory support and dosimetry reporting. Services include agent-specific imaging protocol design, centralized vendor-independent SPECT/CT quantitative reconstruction with advanced scatter and crosstalk compensation, and expert dosimetry analysis to optimize patient outcomes and reduce normal organ toxicity. Rapid also develops software solutions, including 3D-RD-S, a SaaS platform for radiopharmaceutical dosimetry calculations and radiobiological response modeling. The company combines 45+ years of NIH-funded research and development experience to standardize and simplify dosimetry for routine precision dosing of radiopharmaceutical therapies.